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Background: Many patients with chronic obstructive pulmonary disease (COPD) 
 continue to suffer exacerbations, even when treated with maximum recommended therapy 
(eg, inhaled combinations of long-acting β
2
-agonist and high dose inhaled corticosteroids, with 
or without a long-acting anticholinergic [long-acting muscarinic antagonist]). Roflumilast is 
approved to treat severe COPD in patients with chronic bronchitis – and a history of frequent 
exacerbations – as an add-on to bronchodilators.
Purpose: The REACT (Roflumilast in the Prevention of COPD Exacerbations While T aking 
Appropriate Combination Treatment) study (identification number RO-2455-404-RD, clini-
caltrials.gov identifier NCT01329029) will investigate whether roflumilast further reduces 
exacerbations when added to inhaled combination therapy in patients still suffering from 
frequent exacerbations.
Patients and methods: REACT is a 1-year randomized, double-blind, multicenter, 
phase III/IV study of roflumilast 500 µg once daily or placebo on top of a fixed long-acting 
β
2
-agonist/inhaled corticosteroid combination. A concomitant long-acting muscarinic antagonist 
will be allowed at stable doses. The primary outcome is the rate of moderate or severe COPD 
exacerbations. Using a Poisson regression model with a two-sided significance level of 5%, 
a sample size of 967 patients per treatment group is needed for 90% power. COPD patients 
with severe to very severe airflow limitation, symptoms of chronic bronchitis, and at least two 
exacerbations in the previous year will be recruited.
Conclusion: It is hypothesized that because roflumilast (a phosphodiesterase-4 inhibitor) has a 
different mode of action to bronchodilators and inhaled corticosteroids, it may provide additional 
benefits when added to these treatments in frequent exacerbators. REACT will be important 
to determine the role of roflumilast in COPD management. Here, the design and rationale for 
this important study is described.
Keywords: chronic obstructive pulmonary disease, roflumilast, protocol, LABA, ICS, 
exacerbation
Introduction
There is a wide variety of pharmacological treatments currently available for chronic 
obstructive pulmonary disease (COPD). However, it is clear that even dual or triple 
combination therapy with long-acting bronchodilators and inhaled steroids is insuf-
ficient to prevent exacerbations in patients with severe to very severe disease.
Although COPD care has improved over the last decade,1 there is still a huge 
unmet burden of disease. Exacerbations in particular can be distressing for patients2 
and have serious consequences on their long-term health, such as increased disease 
progression,3 increased risk of cardiovascular events,4 and increased mortality rates.5,6 
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Management of stable COPD should be based not only on 
addressing the current disease impact (determined mainly 
by symptoms and activity limitation) but also by reducing 
the patient’s future risk of disease progression (determined 
primarily by exacerbation frequency).7 In clinical prac-
tice, patients still suffering from frequent exacerbations 
may already be treated with a combination of long-acting 
β
2
-agonists (LABA) and inhaled corticosteroids (ICS), often 
in addition to tiotropium (a long-acting muscarinic antago-
nist [LAMA]). Since frequent exacerbations are associated 
with a high level of inflammation,8,9 it is logical to add an 
antiinflammatory therapy to combination treatment in order 
to further reduce exacerbation risk.
Roflumilast is an antiinflammatory treatment that 
reduces exacerbation frequency in a specific subgroup of 
COPD patients with severe airflow limitation, a previous 
history of exacerbations, and symptoms of chronic cough 
and sputum.10,11 These features are typical of patients in 
group D as classified in the latest recommendations from 
Global Initiative for Obstructive Lung Disease (GOLD).12 
In this patient population, the effects of roflumilast are 
additive when it is added on top of monotherapy with either 
LABA or LAMA,10,11 and even when used together with 
ICS.13 However, the effects of roflumilast added on top of 
dual or triple therapy have not been studied in a clinical 
trial setting. It is hypothesized that roflumilast will provide 
additional benefit when used with these other therapeutic 
combinations.
The REACT (Roflumilast in the Prevention of COPD 
Exacerbations While Taking Appropriate Combination Treat-
ment) study (trial identification number RO-2455-404-RD, 
clinicaltrials.gov identifier NCT01329029) is designed to 
test this hypothesis and also to set in context the side effect 
profile of roflumilast identified in earlier investigations. This 
study will involve a double-blind placebo-controlled parallel 
group. Exposure to roflumilast will be over 12 months, with 
an extended follow-up period of 3 months, to determine both 
the subsequent occurrence of exacerbations and the revers-
ibility of any adverse effects. The data from this trial will 
give insight as to whether drug therapies of different classes 
can be effectively combined to prevent exacerbations.
Material and methods
REACT study design
REACT is a 52-week randomized, double-blind, parallel group, 
multicenter, phase III/IV study (Figure 1). It includes a 4-week 
run-in period during which all patients will receive placebo in 
addition to their existing fixed LABA/ICS combination. This is 
followed by a 52-week treatment period during which patients 
will be randomized 1:1 to placebo or once-daily roflumilast 
500 µg in addition to the fixed LABA/ICS combination. Any 
commercially available fixed LABA/ICS combination may 
be used, at the maximum dosage approved in each country. 
This is the medication previously used by the patient and will 
not be supplied by the sponsor. Allowed concomitant medica-
tions include a LAMA – salbutamol – as rescue medication, 
Single-blind
baseline period:
4 weeks
Double-blind
treatment period:
52 weeks
Roflumilast 500 µg once daily
End of treatmentR
Placebo once daily
Placebo once daily
Fixed combination of LABA and ICS
Safety
follow-up
30 days
after Vend
Follow-up
visit after
12 weeks
Figure 1 REACT (Roflumilast in the Prevention of Chronic Obstructive Pulmonary Disease Exacerbations While Taking Appropriate Combination Treatment) study design.
Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; R, randomization; Vend, last visit.
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and antibiotics and glucocorticoids may be used to treat 
exacerbations. Drugs to treat concurrent diseases are also 
allowed. A 30-day follow-up period is included to monitor any 
ongoing adverse events, with a final follow-up visit 12 weeks 
after the end of treatment. Compliance will be determined 
based on the number of tablets taken and the number of days in 
the treatment period. Compliance must be $80% and #125% 
during the 4-week baseline period in order for patients to be 
randomized (Appendix 1), and must be $70% and #143% 
during the 1-year treatment period.
Patient participation
A total of 1934 patients will be randomized (967 per treat-
ment arm). Patients will be recruited from approximately 200 
centers in 21 countries worldwide. All patients must have 
COPD with severe airflow limitation (confirmed by a post-
bronchodilator forced expiratory volume in 1 second [FEV
1
]/
forced vital capacity ratio of 0.70 and a postbronchodilator 
FEV
1
 of ,50% predicted), symptoms of chronic bronchitis 
and a history of frequent exacerbations (at least two in the 
previous year), and must have been on stable treatment with a 
LABA/ICS fixed combination for $12 months prior to study 
start. A list of inclusion and exclusion criteria is provided 
in Appendix 2. This study will be conducted in compliance 
with the Clinical Trial Protocol, the International Conference 
on Harmonization Consolidated Good Clinical Practices 
Guideline, the Declaration of Helsinki, and any applicable 
national regulations. All patients will give informed consent 
to participate in the study.
Endpoints
The primary endpoint is the rate of moderate or severe COPD 
exacerbations per patient per year. Moderate exacerbations 
are defined as requiring oral or parenteral glucocorticoids. 
Severe exacerbations are defined as requiring hospitaliza-
tion and/or leading to death. The key secondary endpoint 
measured in REACT is the change in postbronchodilator 
FEV
1
 from randomization to the end of the 52-week treat-
ment period, assessed by spirometry. Other endpoints are 
described in Appendix 3. Quality of life will be measured 
using the COPD Assessment Test™ (GlaxoSmithKline, 
Middlesex, United Kingdom). Safety endpoints include the 
number of adverse events and changes in body weight/body 
mass index.
COPD exacerbations
Patients experiencing an exacerbation during the run-in 
period cannot be entered into the treatment period until after 
the exacerbation has resolved. COPD symptoms (cough, 
sputum) and use of rescue medication will be recorded on 
a daily basis in the patient diary to increase the patient’s 
awareness of worsening COPD symptoms. To ensure that 
all exacerbations are captured, patients will be encouraged 
to contact their study doctor in case of a deterioration of 
COPD symptoms. All exacerbations will be captured in 
the exacerbation section of the case report form, including 
description of severity, whether treatment was required, 
whether the patient was withdrawn from the study, and 
start/end date of the exacerbation. The number of moderate 
or severe exacerbations during the treatment period will be 
recorded and analyzed as the primary endpoint. A number of 
other exacerbation endpoints will also be assessed, including 
the proportion of patients experiencing an exacerbation and 
time to first, second, and third exacerbation.
Statistical analysis
The primary endpoint rate of moderate or severe COPD 
exacerbations will be analyzed with a Poisson regression 
model with the number of exacerbations per patient as the 
dependent variable. The model will include an offset variable 
representing the duration of a patient in the study. Treatment 
will be included as independent variable in the model. 
A correction for overdispersion will be considered.
Assuming a mean exacerbation rate of 1.25 per patient 
per year in the placebo group and a reduction in exacerba-
tions of 20% with roflumilast 500 µg, and using a Poisson 
regression model with a correction for overdispersion of two 
based on previous data,10 it was estimated that 967 patients 
per treatment group would provide 90% power to detect a 
significant difference between treatments with a two-sided 
α level of 0.05.
To evaluate the effect of study medication discontinu-
ation on the primary endpoint, results including all exacer-
bations occurring during the 1-year study period (on- and 
off-treatment) will be provided as a key sensitivity analysis.
The secondary endpoints from spirometry, use of rescue 
medication, symptom scores, as well as the COPD Assess-
ment Test will be analyzed using a repeated measurements 
model. The dependent variable will be the change from 
randomization to each scheduled postrandomization visit. As 
independent variables, the following factors and covariates 
(all fixed) will be included: treatment, baseline value, time, 
and a treatment-by-time interaction.
Time to first, second, and third COPD exacerbation 
(combined in one analysis) will be analyzed according to 
the method of Wei–Lin–Weissfeld.14 In addition, time to 
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first, second, and third exacerbation (separate analyses) as 
well as time to mortality and time to study withdrawal will 
be analyzed using the Cox proportional hazards regression. 
A responder analysis of patients with at least one COPD 
exacerbation (exacerbators) or without any COPD exacer-
bation (nonexacerbators) will be performed based on both 
on- and off-treatment data.
Safety analyses will be performed descriptively.
Discussion
The REACT study will address a most important clini-
cally relevant question: whether an oral antiinflammatory 
phosphodiesterase-4 (PDE4) inhibitor will provide additional 
benefit in patients already treated and not fully controlled 
with inhaled LABA/ICS combination therapy and, in a 
proportion of patients, tiotropium (LAMA). In addition, the 
study will provide important new information on the safety 
of roflumilast in these patients.
Over the last decade, large pharmacological interven-
tion studies have not only determined the evidence base for 
current COPD therapy, but have also allowed a series of 
problems relevant to the daily life of COPD patients to be 
addressed. In addition, trials of new treatments have taken 
place.15 There is now a clear understanding of the interrela-
tions between exacerbations and impaired health status, 
the patterns of mortality in COPD,16,17 the significance of 
withdrawing from clinical trials,18 and the most appropriate 
way of expressing exacerbation rates in interventional and 
observational studies.19,20 To date, the majority of these large 
clinical studies have involved inhaled therapies such as ICS, 
LABA, LAMA, and combinations of these agents in the 
same and different inhalers. Studies of PDE4 inhibitors have 
also contributed to the knowledge of COPD, with data from 
biopsy studies with cilomilast21 and induced sputum data with 
roflumilast and cilomilast22 showing that these antiinflam-
matory agents can affect the cellular profile in patients with 
stable disease, unlike exposure to ICS monotherapy over a 
similar period of a few weeks.23,24 These studies confirmed 
the findings of in vitro experiments which showed that 
PDE4 inhibitors have multiple potential actions on cells 
involved in persistent inflammation. However, translating 
these observations into clinical practice is challenging and 
has provided some further insight into how agents of different 
classes should be tested.
Although several PDE4 inhibitors have been developed 
by many pharmaceutical companies, only cilomilast and 
roflumilast eventually proceeded to large scale trials in 
humans. The initially encouraging results seen after 6 weeks 
of treatment with cilomilast in COPD patients of moderate 
severity were not confirmed in a consistent way in 6-month 
studies conducted in patients with more severe disease; 
although positive effects on inflammatory markers in sputum 
have been reported.25 The changes in lung function in these 
studies were modest in contrast to the changes in FEV
1
 seen 
with roflumilast in the dose-ranging RECORD study.26 The 
majority of patients in this clinical trial had GOLD Stage II 
COPD and the number reporting exacerbations requiring 
treatment with corticosteroids and/or antibiotics was small. 
In the next phase, using the 500 µg once-daily dose of 
roflumilast, which is the approved treatment dose, the results 
were disappointing. A statistically significant improvement in 
FEV
1
 was seen in patients with GOLD Stage III/IV COPD but 
there was no statistically significant difference in the number 
of exacerbations in those treated with roflumilast compared 
with placebo.27 The exacerbation rate in this study was lower 
than anticipated and when subgroups with more severe 
disease and a history of chronic bronchitis symptoms were 
studied, where the exacerbation rate was higher, then there 
was evidence of a positive treatment effect.13 Subsequently, 
two identical prospective clinical trials were conducted to 
test the hypothesis that, in a specific subset of patients prone 
to exacerbations, roflumilast may reduce the exacerbation 
rate. COPD patients with a history of prior exacerbations 
requiring medical treatment, confirmed symptoms of chronic 
bronchitis, and an FEV
1
 of ,50% predicted were recruited 
and randomized to treatment over 1 year. In this study, 
patients were asked not to take ICS in case this confounded 
the action of the antiinflammatory drug, but 50% were 
allowed to continue with LABA. The results of these studies 
have been published10 and confirm that there was a positive 
improvement in both of the primary endpoints in each case. 
A subsequent prespecified analysis revealed that in patients 
concomitantly treated with LABA, the addition of roflumilast 
further reduced the mean exacerbation rate by 21% (rela-
tive risk 0.79; P , 0.001).28 A posthoc analysis of the early 
roflumilast trials, in which concomitant treatment with ICS 
at a stable dose was allowed, showed that roflumilast provides 
further reductions in exacerbations also in patients using 
ICS.13 Finally, in two 6-month trials in patients with GOLD 
Stage II–IV COPD, an additive effect was seen in terms of 
lung function improvement when roflumilast was added either 
to salmeterol (LABA) or tiotropium (LAMA).11
However, as COPD patients often are treated with a com-
bination of drug classes, additional data are clearly needed 
about whether the addition of roflumilast can further reduce 
exacerbation frequency in patients who have exacerbations 
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and meet the other criteria already noted despite taking a 
LABA/ICS combination or triple therapy with LABA/ICS 
and tiotropium. Based on the pharmacology of roflumilast, 
the pathways modified are different from those changed by 
bronchodilators and ICS, but this is no guarantee that this 
will translate into clinically meaningful improvement. It is 
reassuring that analyses of previous studies which allowed 
concomitant therapy suggested incremental efficacy with 
roflumilast when used either with bronchodilators11,28 or 
ICS.13 However, these studies could not provide insight into 
the benefit of roflumilast added to various combinations of 
different therapeutic drug classes such as LABA/ICS therapy 
or LABA/ICS/LAMA triple therapy, which is the goal of the 
current study. The LABA/ICS combinations used in REACT 
may be any commercially available fixed dose combination, 
used at the maximum dose approved in each country. While 
this introduces some variability in the study, this design will 
reflect that in real life roflumilast will not be added to the 
same drug regimen in every patient, which means that the 
results are relevant to patients around the world.
Most oral therapies are associated with side effects and 
issues of patient tolerance, and roflumilast is associated 
with a series of pharmacologically predictable side effects. 
When data were pooled from 14 randomized, double-blind, 
placebo-controlled studies of roflumilast in COPD patients 
(5766 patients in total treated with roflumilast and 5491 with 
placebo), the most frequent adverse events occurring more 
commonly with roflumilast versus placebo were diarrhea 
(10.1% versus 2.6%), weight decrease (6.8% versus 1.8%), 
nausea (5.2% versus 1.4%), and headache (4.6% versus 
2.0%). Apart from weight decrease, the majority of these 
adverse events resolved within 3 weeks (Table 1). Pooling 
safety data in this way has revealed an established side effect 
profile that will be monitored in REACT to see if it is modi-
fied by concomitant use of COPD treatment combinations.
With regard to weight decrease, the absolute magnitude 
was greatest in those people who were heaviest, specifically 
in those who would be classed as obese with a body mass 
index greater than 30. A low body mass index is widely 
regarded as a poor prognostic feature in COPD,29,30 and so any 
drug which reduces body weight needs to be fully understood. 
There are very limited data in the current safety database 
about patients followed after the end of the clinical trial. 
Those data suggest that the patients who have lost weight 
will regain that weight, but clearly more careful prospectively 
collected information is needed.31 For this reason, the REACT 
study includes an extended period of follow-up of the study 
medication. The occurrence of exacerbations will also be 
monitored, as withdrawal of ICS has been associated with an 
increase in exacerbations.32 This will provide further insight, 
not only into the action of this drug, but also as to whether 
withdrawal studies could be seen as a more cost-efficient 
way of evaluating new treatments.
Conclusion
In summary, data from the REACT trial will add consider-
ably to the knowledge of COPD in symptomatic patients 
with severe airflow limitation who are particularly at risk of 
exacerbating despite treatment with LABA/ICS combination 
or LABA/ICS/LAMA triple therapy. It will be determined 
whether there is a ceiling effect for pharmacological treat-
ment in this condition, or whether – despite current best 
efforts – more can be offered to these high risk patients who 
continue to suffer from exacerbations. Moreover, the profile 
of adverse events should be able to be better understood now 
that it is clearer which events occur most often and which 
require objective monitoring. Studies such as this will con-
tinue to advance knowledge in COPD and ensure that future 
treatment guidance is based on firm evidence from carefully 
conducted clinical trials.
Table 1 Adverse events reported with once-daily placebo or roflumilast in the chronic obstructive pulmonary disease safety pool
Duration of adverse  
events, weeks
Diarrhea Weight decrease Nausea Headache
PBO  
(n = 5491)
ROF  
(n = 5766)
PBO  
(n = 5491)
ROF  
(n = 5766)
PBO  
(n = 5491)
ROF  
(n = 5766)
PBO  
(n = 5491)
ROF  
(n = 5766)
,1 88 (55.3) 228 (32.5) 0 (0) 0 (0) 38 (45.2) 102 (30.5) 72 (57.1) 114 (38.8)
1–3 41 (25.8) 258 (36.8) 3 (3.0) 24 (6.0) 28 (33.3) 144 (43.1) 24 (19.0) 93 (31.6)
4–12 20 (12.6) 140 (20.0) 16 (15.8) 82 (20.4) 12 (14.3) 59 (17.7) 15 (11.9) 55 (18.7)
13–25 4 (2.5) 46 (6.6) 15 (14.9) 83 (20.7) 3 (3.6) 18 (5.4) 4 (3.2) 11 (3.7)
$26 2 (1.3) 14 (2.0) 16 (15.8) 88 (21.9) 1 (1.2) 4 (1.2) 3 (2.4) 8 (2.7)
Ongoing or missing recovery date 4 (2.5) 15 (2.2) 51 (50.5) 124 (30.9) 2 (2.4) 7 (2.1) 8 (6.3) 13 (4.4)
Total, n 159 701 101 401 84 334 126 294
Notes: The table includes pooled data from 14 placebo-controlled, double-blind phase II/III studies of roflumilast 500 µg or 250 µg once daily versus placebo in subjects with 
moderate-to-very severe chronic obstructive pulmonary disease. Eight of the 14 studies have been published previously.10,11,26,27,33 Data are presented as number of patients 
(percent of events in each category).
Abbreviations: PBO, placebo; ROF, roflumilast.
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Supplementary data
Appendix 1: randomization criteria
•	 No moderate or severe exacerbation, and/or exacerba-
tion treated with antibiotics, during single-blind baseline 
period
•	 Tablet compliance $80% and #125%
•	 Total cough and sputum score $14 during the last week 
directly preceding randomization visit
•	 A postbronchodilator forced expiratory volume in 
1 second (FEV
1
) of #50% predicted.
Appendix 2: inclusion and exclusion 
criteria for the REACT (Roflumilast  
in the Prevention of Chronic Obstructive 
Pulmonary Disease Exacerbations 
While Taking Appropriate Combination 
Treatment) study
Key inclusion criteria
•	 Male or female aged $40 years
•	 Current or former smoker with a smoking history 
of $20 pack years
•	 History of chronic obstructive pulmonary disease 
(diagnosed $12 months prior to study start) associated 
with chronic productive cough (for 3 months in each of 
the 2 years prior to study start)
•	 Postbronchodilator FEV
1
/forced vital capacity ratio 
of ,70% predicted and FEV
1
 of #50% predicted
•	 History of at least two exacerbations in the past year
•	 Treated with fixed long-acting β
2
-agonist/inhaled corti-
costeroid combination at a constant dose (the maximum 
approved strength) for $12 months prior to study start.
Key exclusion criteria
•	 Ongoing exacerbation at study start (moderate or severe, 
or requiring antibiotics)
•	 Lower respiratory tract infection not resolved within 
4 weeks prior to study start
•	 Diagnosis of asthma or other relevant lung disease
•	 Current or recent (within 3 months of study start) partici-
pation in a pulmonary rehabilitation program
•	 Known α1-antitrypsin deficiency.
Appendix 3: secondary and other 
endpoints in the REACT (Roflumilast  
in the Prevention of Chronic Obstructive 
Pulmonary Disease Exacerbations 
While Taking Appropriate Combination 
Treatment) study
Secondary efficacy endpoints
•	 Change in postbronchodilator FEV
1
 (key secondary 
endpoint)
•	 Other chronic obstructive pulmonary disease exacerba-
tion (mild, increase in rescue medication of at least three 
puffs per day on at least two consecutive days during the 
double-blind treatment period; moderate, requiring oral or 
parenteral glucocorticoid therapy; and severe, requiring 
hospitalization and/or leading to death) endpoints
•	 Postbronchodilator lung function measurements
•	 Patient diary endpoints
•	 Quality of life (COPD Assessment Test™; GlaxoSmith-
Kline, Middlesex, United Kingdom)
•	 Mortality
•	 Time to withdrawal.
Other endpoints
•	 Pharmacokinetics and pharmacodynamics of roflumilast 
and roflumilast amine oxide
•	 Safety
•	 Adverse events
•	 Changes in laboratory values, vital signs, and physical 
examination findings (eg, electrocardiogram)
•	 Changes in body weight and body mass index.
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